Interim results of phase II study BRF113928 of dabrafenib in BRAF V600E mutation–positive non-small cell lung cancer (NSCLC) patients.
David Planchard
No relevant relationships to disclose
Julien Mazieres
No relevant relationships to disclose
Gregory J. Riely
Consultant or Advisory Role - ARIAD; Celgene; Chugai Pharma; Daiichi Sankyo; Foundation Medicine; Novartis; Tragara Pharmaceuticals
Research Funding - Bristol-Myers Squibb; Chugai Pharma; Concordia Pharmaceuticals; GlaxoSmithKline; Infinity; Merck; Millennium; Novartis; Pfizer
Charles M. Rudin
Consultant or Advisory Role - AVEO; Lilly; Oncothyreon
Fabrice Barlesi
No relevant relationships to disclose
Elisabeth A. Quoix
No relevant relationships to disclose
Pierre Jean Souquet
Honoraria - GlaxoSmithKline
Mark A. Socinski
Research Funding - GlaxoSmithKline
Julie Switzky
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Bo Ma
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Vicki L. Goodman
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Stanley W. Carson
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
C. Martin Curtis
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Michael R. W. Streit
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Bruce E. Johnson
Consultant or Advisory Role - Acceleron Pharma; AstraZeneca; Chugai Pharma; Genentech; KEW Group; Millennium; Pfizer; Transgenomic
Stock Ownership - KEW Group
Honoraria - Acceleron Pharma; AstraZeneca; Chugai Pharma; Genentech; KEW Group; Millennium; Pfizer; Transgenomic
Other Remuneration - Response Genetics